{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:08:24Z","timestamp":1792656504223,"version":"4.5.0"},"reference-count":113,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Chronic hepatitis B (CHB) infection is a significant risk factor for developing hepatocellular carcinoma (HCC). As HCC is associated with significant morbidity and mortality, screening patients with CHB at a high risk for HCC is recommended in an attempt to improve these outcomes. However, the screening recommendations on who to screen and how often are not uniform. Identifying patients at the highest risk of HCC would allow for the best use of health resources. In this review, we evaluate the literature on screening patients with CHB for HCC, strategies for optimizing adherence to screening, and potential risk stratification tools to identify patients with CHB at a high risk of developing HCC.<\/jats:p>","DOI":"10.3390\/v13071318","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T10:42:17Z","timestamp":1625740937000},"page":"1318","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Screening for Hepatocellular Carcinoma in Patients with Hepatitis B"],"prefix":"10.3390","volume":"13","author":[{"given":"Yashasavi","family":"Sachar","sequence":"first","affiliation":[{"name":"London Health Sciences Center, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 5A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Brahmania","sequence":"additional","affiliation":[{"name":"London Health Sciences Center, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 5A5, Canada"},{"name":"Centre for Quality, Innovation and Safety, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renumathy","family":"Dhanasekaran","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3531","authenticated-orcid":false,"given":"Stephen E.","family":"Congly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada"},{"name":"O\u2019Brien Institute of Public Health, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rahib, L., Wehner, M.R., Matrisian, L.M., and Nead, K.T. (2021). Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw. Open, 4.","DOI":"10.1001\/jamanetworkopen.2021.4708"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of Primary Liver Cancer to 2030 in 30 Countries Worldwide","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of Hepatocellular Carcinoma: Consider the Population","volume":"47","author":"Mittal","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/gutjnl-2020-321627","article-title":"Prioritisation and the Initiation of HCC Surveillance in CHB Patients: Lessons to Learn from the COVID-19 Crisis","volume":"69","author":"Zeng","year":"2020","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular Carcinoma: Epidemiology, Risk Factors and Pathogenesis","volume":"14","author":"Gomaa","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s15010-019-01345-y","article-title":"Epidemiological and Etiological Variations in Hepatocellular Carcinoma","volume":"48","author":"Sagnelli","year":"2020","journal-title":"Infection"},{"key":"ref_9","first-page":"2857","article-title":"High Prevalence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Thailand","volume":"17","author":"Wanich","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fvl.13.11","article-title":"Viral Hepatitis in Resource-Limited Countries and Access to Antiviral Therapies: Current and Future Challenges","volume":"8","author":"Lemoine","year":"2013","journal-title":"Future Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2893.2010.01333.x","article-title":"Factors Associated with Vaccine Failure and Vertical Transmission of Hepatitis B among a Cohort of Canadian Mothers and Infants","volume":"18","author":"Singh","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lu, M., Zhou, Y., Holmberg, S.D., Moorman, A.C., Spradling, P.R., Teshale, E.H., Boscarino, J.A., Daida, Y.G., Schmidt, M.A., and Li, J. (2019). Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006\u20132015. Open Forum Infect. Dis., 6.","DOI":"10.1093\/ofid\/ofz286"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of Chronic Hepatitis B Virus Infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/MCG.0000000000000810","article-title":"Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-Based Study","volume":"51","author":"Yang","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_17","first-page":"34","article-title":"What Makes a Screening Exam \u201cGood\u201d?","volume":"8","author":"Herman","year":"2006","journal-title":"Virtual Mentor VM"},{"key":"ref_18","unstructured":"Wilson, J.M.G., and Jungner, G. (1968). Principles and Practice of Screening for Disease, World Health Organization."},{"key":"ref_19","first-page":"296","article-title":"Quality of Life and Hepatocellular Carcinoma","volume":"5","author":"Gandhi","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3138\/canlivj.2018-0008","article-title":"Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada","volume":"1","author":"Coffin","year":"2018","journal-title":"Can. Liver J."},{"key":"ref_21","unstructured":"(2018). European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF01438313","article-title":"Prospective Study of Early Detection for Primary Liver Cancer","volume":"123","author":"Yang","year":"1997","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized Controlled Trial of Screening for Hepatocellular Carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/M14-0558","article-title":"Screening for Hepatocellular Carcinoma in Chronic Liver Disease: A Systematic Review","volume":"161","author":"Kansagara","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1258\/096914103771773320","article-title":"Screening for Liver Cancer: Results of a Randomised Controlled Trial in Qidong, China","volume":"10","author":"Chen","year":"2003","journal-title":"J. Med. Screen."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Pillai, A., and Tiro, J. (2014). Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-Analysis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001624"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural History of Hepatitis C Virus Infection in HIV-Infected Individuals and the Impact of HIV in the Era of Highly Active Antiretroviral Therapy: A Meta-Analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS Lond. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MCG.0000000000000708","article-title":"Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-Based Integrated Health Care Delivery System","volume":"51","author":"Singal","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cgh.2018.10.031","article-title":"Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis","volume":"17","author":"Choi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep4.1047","article-title":"Long-Term Survival after Surveillance and Treatment in Patients with Chronic Viral Hepatitis and Hepatocellular Carcinoma","volume":"1","author":"Tong","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1053\/j.gastro.2018.06.079","article-title":"No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis","volume":"155","author":"Moon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_36","unstructured":"PDQ (2002). Screening and Prevention Editorial Board Liver (Hepatocellular) Cancer Screening (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries, National Cancer Institute (US)."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jhep.2016.10.015","article-title":"Geographical Variations in Incidence, Management and Survival of Hepatocellular Carcinoma in a Western Country","volume":"66","author":"Sogni","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.1840120625","article-title":"Alpha-Fetoprotein: Reevaluation in Hepatology","volume":"12","author":"Taketa","year":"1990","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and Significance of Alpha-fetoprotein in Hepatocellular Carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s005350200111","article-title":"Is AFP a New Reliable Marker of Liver Regeneration in Acute Hepatic Failure?","volume":"37","author":"Takikawa","year":"2002","journal-title":"J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jceh.2013.02.246","article-title":"Elevated Alpha Fetoprotein, No Hepatocellular Carcinoma","volume":"3","author":"Patil","year":"2013","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-Analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","article-title":"A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk","volume":"3","author":"Frenette","year":"2019","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver Diseases Management of Hepatocellular Carcinoma: An Update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic Hepatitis D and Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Farci, P., Niro, G.A., Zamboni, F., and Diaz, G. (2021). Hepatitis D Virus and Hepatocellular Carcinoma. Viruses, 13.","DOI":"10.3390\/v13050830"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.25321","article-title":"Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis","volume":"128","author":"Cho","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11901-020-00541-x","article-title":"Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy","volume":"19","author":"Kim","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11904-019-00475-0","article-title":"Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies","volume":"17","author":"Merchante","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jval.2020.11.014","article-title":"A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies","volume":"24","author":"Nguyen","year":"2021","journal-title":"Value Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.7314\/APJCP.2014.15.20.8993","article-title":"Economic Evaluation and Budget Impact Analysis of the Surveillance Program for Hepatocellular Carcinoma in Thai Chronic Hepatitis B Patients","volume":"15","author":"Sangmala","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1440-1746.1992.tb01021.x","article-title":"Analysis of Cost-Effectiveness of Different Strategies for Hepatocellular Carcinoma Screening in Hepatitis B Virus Carriers","volume":"7","author":"Kang","year":"1992","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_54","first-page":"546","article-title":"Screening for Hepatocellular Carcinoma (HCC): Is It Cost-Effective?","volume":"22","author":"Lam","year":"2000","journal-title":"Hong Kong Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2008.12.022","article-title":"Antiviral Therapy for Hepatitis B-Related Liver Cancer Prevention Is More Cost-Effective than Cancer Screening","volume":"50","author":"Robotin","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2753.2010.01432.x","article-title":"Cost-Effectiveness of Screening for Hepatocellular Carcinoma among Subjects at Different Levels of Risk","volume":"17","author":"Chang","year":"2011","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/1940-6207.CAPR-12-0046","article-title":"Failure Rates in the Hepatocellular Carcinoma Surveillance Process","volume":"5","author":"Singal","year":"2012","journal-title":"Cancer Prev. Res. Phila. Pa"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Marquardt, P., Liu, P., Immergluck, J., Olivares, J., Arroyo, A., Rich, N.E., Parikh, N.D., Yopp, A.C., and Singal, A.G. (2021). Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol. Commun.","DOI":"10.1002\/hep4.1735"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/gastro\/gou089","article-title":"Perspectives of Physicians Regarding Screening Patients at Risk of Hepatocellular Carcinoma","volume":"4","author":"Bharadwaj","year":"2016","journal-title":"Gastroenterol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"90.e1","DOI":"10.1016\/j.amjmed.2014.07.027","article-title":"Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance","volume":"128","author":"Singal","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.28770","article-title":"Patient-Reported Barriers Are Associated with Lower Hepatocellular Carcinoma Surveillance Rates in Patients with Cirrhosis","volume":"65","author":"Farvardin","year":"2017","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.28765","article-title":"Identifying Barriers to Hepatocellular Carcinoma Surveillance in a National Sample of Patients with Cirrhosis","volume":"65","author":"Goldberg","year":"2017","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cgh.2018.07.029","article-title":"Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance","volume":"17","author":"Simmons","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_66","first-page":"791","article-title":"Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients with Cirrhosis","volume":"13","author":"Tiro","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.30129","article-title":"Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial","volume":"69","author":"Singal","year":"2019","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijn.12472","article-title":"Nurse-Led Hepatocellular Carcinoma Surveillance Clinic Provides an Effective Method of Monitoring Patients with Cirrhosis","volume":"22","author":"Nazareth","year":"2016","journal-title":"Int. J. Nurs. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/imj.12166","article-title":"Optimisation of Hepatocellular Carcinoma Surveillance in Patients with Viral Hepatitis: A Quality Improvement Study","volume":"43","author":"Kennedy","year":"2013","journal-title":"Intern. Med. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.crad.2016.10.019","article-title":"Ultrasound Surveillance for Hepatocellular Carcinoma: Service Evaluation of a Radiology-Led Recall System in a Tertiary-Referral Centre for Liver Diseases in the UK","volume":"72","author":"Farrell","year":"2017","journal-title":"Clin. Radiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wu, S., Zeng, N., Sun, F., Zhou, J., Wu, X., Sun, Y., Wang, B., Zhan, S., Kong, Y., and Jia, J. (2021). Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin. Gastroenterol. Hepatol.","DOI":"10.1016\/j.cgh.2021.02.040"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/TP.0000000000002945","article-title":"Distinguishing between Sex and Gender Is Critical for Research in Transplantation","volume":"104","author":"Congly","year":"2019","journal-title":"Transplantation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000082091","article-title":"How to Predict HCC Development in Patients with Chronic B Viral Liver Disease?","volume":"48","author":"Han","year":"2005","journal-title":"Intervirology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C Hepatitis B Virus Infection Is Associated with an Increased Risk of Hepatocellular Carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/gutjnl-2014-309099","article-title":"The Applicability of Hepatocellular Carcinoma Risk Prediction Scores in a North American Patient Population with Chronic Hepatitis B Infection","volume":"65","author":"Cerocchi","year":"2016","journal-title":"Gut"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.20517\/2394-5079.2020.114","article-title":"Statistical Strategies for HCC Risk Prediction Models in Patients with Chronic Hepatitis B","volume":"2021","author":"Yip","year":"2021","journal-title":"Hepatoma Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2013.09.029","article-title":"Liver Stiffness-Based Optimization of Hepatocellular Carcinoma Risk Score in Patients with Chronic Hepatitis B","volume":"60","author":"Wong","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.21420","article-title":"Accuracy of Liver Stiffness Measurement for the Diagnosis of Cirrhosis in Patients with Chronic Liver Diseases","volume":"44","author":"Ziol","year":"2006","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jhep.2015.05.019","article-title":"Can We Use HCC Risk Scores to Individualize Surveillance in Chronic Hepatitis B Infection?","volume":"63","author":"Wong","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent Risk Factors and Predictive Score for the Development of Hepatocellular Carcinoma in Chronic Hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B): Development and Validation of a Predictive Score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.12144","article-title":"Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) Score in Classifying Treatment Eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) Guideline for Chronic Hepatitis B Patients","volume":"37","author":"Chen","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_84","first-page":"233","article-title":"Carcinoma Hepatocelular Em Doentes Com Infec\u00e7\u00e3o Cr\u00f3nica Pelo V\u00edrus Da Hepatite B Sob An\u00e1logos Dos Nucle\u00f3s(t)Idos de 3a Gera\u00e7\u00e3o: Factores de Risco e o Desempenho de Um Score de Risco","volume":"23","author":"Lebre","year":"2016","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"AMAP Risk Score Predicts Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Alempijevic, T.M., Stojkovic Lalosevic, M., Dumic, I., Jocic, N., Markovic, A.P., Dragasevic, S., Jovicic, I., Lukic, S., Popovic, D., and Milosavljevic, T. (2017). Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients. Can. J. Gastroenterol. Hepatol., 2017.","DOI":"10.1155\/2017\/6070135"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jhep.2020.10.008","article-title":"External Validation of AMAP Risk Score in Patients with Chronic Hepatitis C Genotype 4 and Cirrhosis Who Achieved SVR Following DAAs","volume":"74","author":"Shiha","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1136\/gutjnl-2015-310818","article-title":"Real-World Risk Score for Hepatocellular Carcinoma (RWS-HCC): A Clinically Practical Risk Predictor for HCC in Chronic Hepatitis B","volume":"65","author":"Poh","year":"2016","journal-title":"Gut"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","article-title":"Nomograms for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection","volume":"28","author":"Yang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/liv.12621","article-title":"Liver Stiffness-Based Model for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection: Comparison with Histological Fibrosis","volume":"35","author":"Shin","year":"2015","journal-title":"Liver Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000335430","article-title":"Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement","volume":"85","author":"Kim","year":"2012","journal-title":"Digestion"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2018-316525","article-title":"A Simple AGED Score for Risk Classification of Primary Liver Cancer: Development and Validation with Long-Term Prospective HBsAg-Positive Cohorts in Qidong, China","volume":"68","author":"Fan","year":"2019","journal-title":"Gut"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5009\/gnl16403","article-title":"A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels","volume":"11","author":"Sinn","year":"2017","journal-title":"Gut Liver"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B Predicts the Risk of Developing Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B on 5-Year Antiviral Therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jgh.14990","article-title":"Validation of Hepatocellular Carcinoma Risk Scores in Japanese Chronic Hepatitis B Cohort Receiving Nucleot(s)Ide Analog","volume":"35","author":"Kirino","year":"2020","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the Accuracy of PAGE-B-Related Scores to Predict Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B","volume":"72","author":"Yip","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/liv.13450","article-title":"Validation of PAGE-B Model in Asian Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ajg.2014.157","article-title":"Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy","volume":"109","author":"Lee","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"113213","DOI":"10.18632\/oncotarget.22375","article-title":"Validation of Risk Prediction Models for the Development of HBV-Related HCC: A Retrospective Multi-Center 10-Year Follow-up Cohort Study","volume":"8","author":"Seo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","article-title":"Prediction Model for Hepatocellular Carcinoma Risk in Treatment-Naive Chronic Hepatitis B Patients Receiving Entecavir\/Tenofovir","volume":"31","author":"Yu","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","article-title":"Development of a Scoring System to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B","volume":"69","author":"Hsu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2019.06.028","article-title":"Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy","volume":"18","author":"Kim","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiz477","article-title":"Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy","volume":"221","author":"Yang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk Score Model for the Development of Hepatocellular Carcinoma in Treatment-Na\u00efve Patients Receiving Oral Antiviral Treatment for Chronic Hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/jvh.13485","article-title":"Validation of the HCC-RESCUE Score to Predict Hepatocellular Carcinoma Risk in Caucasian Chronic Hepatitis B Patients under Entecavir or Tenofovir Therapy","volume":"28","author":"Can","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"92431","DOI":"10.18632\/oncotarget.21369","article-title":"Prediction Model of Hepatocellular Carcinoma Risk in Asian Patients with Chronic Hepatitis B Treated with Entecavir","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD Guidelines for the Treatment of Hepatocellular Carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Axley, P., Mudumbi, S., Sarker, S., Kuo, Y.-F., and Singal, A. (2018). Patients with Stage 3 Compared to Stage 4 Liver Fibrosis Have Lower Frequency of and Longer Time to Liver Disease Complications. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197117"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., and Thiele, M. (2021). EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis\u20132021 Update. J. Hepatol.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cld.904","article-title":"Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time","volume":"15","author":"Udompap","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/liv.13889","article-title":"A Combination of the On-Treatment FIB-4 and Alpha-Foetoprotein Predicts Clinical Outcomes in Cirrhotic Patients Receiving Entecavir","volume":"38","author":"Chiang","year":"2018","journal-title":"Liver Int."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Demir, M., Gr\u00fcnewald, F., Lang, S., Schramm, C., Bowe, A., M\u00fcck, V., K\u00fctting, F., Goeser, T., and Steffen, H.-M. (2016). Elevated Liver Fibrosis Index FIB-4 Is Not Reliable for HCC Risk Stratification in Predominantly Non-Asian CHB Patients. Medicine (Baltimore), 95.","DOI":"10.1097\/MD.0000000000004602"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5114\/ceh.2020.102157","article-title":"FIB-5 versus FIB-4 Index for Assessment of Hepatic Fibrosis in Chronic Hepatitis B Affected Patients","volume":"6","author":"Metwally","year":"2020","journal-title":"Clin. Exp. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:41Z","timestamp":1760164061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":113,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071318"],"URL":"https:\/\/doi.org\/10.3390\/v13071318","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}